Antibodies to pituitary surface antigens during various pituitary disease states

in Journal of Endocrinology
Authors:
YM Keda
Search for other papers by YM Keda in
Current site
Google Scholar
PubMed
Close
,
IV Krjukova
Search for other papers by IV Krjukova in
Current site
Google Scholar
PubMed
Close
,
IA Ilovaiskaia
Search for other papers by IA Ilovaiskaia in
Current site
Google Scholar
PubMed
Close
,
MS Morozova
Search for other papers by MS Morozova in
Current site
Google Scholar
PubMed
Close
,
OV Fofanova
Search for other papers by OV Fofanova in
Current site
Google Scholar
PubMed
Close
,
MB Babarina
Search for other papers by MB Babarina in
Current site
Google Scholar
PubMed
Close
,
EI Marova
Search for other papers by EI Marova in
Current site
Google Scholar
PubMed
Close
,
YA Pankov
Search for other papers by YA Pankov in
Current site
Google Scholar
PubMed
Close
, and
VI Kandror
Search for other papers by VI Kandror in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

Autoantibodies to cell surface antigens of human somatotropinoma (ASAS), human prolactinoma (ASAP) and rat adenohypophysis (ASARA) were assayed in the serum of patients with pituitary diseases associated with GH deficiency (GHD), such as pituitary dwarfism and primary empty sella syndrome (ESS), and in the serum of patients with hyperprolactinaemia of different etiologies: idiopathic hyperprolactinaemia, prolactinoma and ESS. The investigation was carried out with a cellular variant of an ELISA. Among children with GHD, the highest percentage of antibody-positive patients was found in the group with idiopathic isolated GHD (89% of ASAS(+) patients and 30% of ASARA(+) patients vs 33.3% and 0% respectively in the group with idiopathic combined pituitary hormone deficiency, and 33.3% and 9% in patients with pituitary hypoplasia associated with isolated GHD or combined pituitary hormone deficiency). Among hyperprolactinaemic patients, the highest ASAP and ASARA frequency was observed in patients with idiopathic hyperprolactinaemia (67.7% and 41.9% respectively) where it was twice as high as in the group of patients with prolactinoma. The proportion of ASAS(+) and ASARA(+) did not differ significantly between the groups of patients with ess with or without GHD. Similarly, there was no significant difference between the number of ESS ASAP(+) and ASARA(+) patients with or without hyperprolactinaemia. The data obtained suggested that autoimmune disorders may be primary, and responsible, at least in part, for pituitary dysfunction in the cases of idiopathic isolated GHD and idiopathic hyperprolactinaemia. At the same time, the autoimmune disorders in the patients with prolactinoma or ESS are probably secondary to the organic pituitary lesion and their significance in the development of the pituitary dysfunction is obscure.